Back to results
US 2022/0023252 A1Published application
Methods of treating chronic kidney disease with dapagliflozin
AssigneeAstraZeneca AB
InventorAnna Maria LANGKILDE
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Claims23
1-59. (canceled)
A method of treating a patient with chronic kidney disease at risk of progression, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin,
- wherein the patient does not have type II diabetes, and
- wherein the method reduces a risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure in the patient relative to a dosing regimen in which the patient receives no dapagliflozin.
A method of treating chronic kidney disease (CKD), comprising administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin,
- wherein the patient does not have type II diabetes,
- wherein the method reduces a risk of an incidence of a composite endpoint in the patient relative to a dosing regimen in which the patient receives no dapagliflozin;
- and
- wherein the composite endpoint is 50% sustained decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease (ESKD), and CV or renal death.
1 more element
Dependencies are inferred from the claim text.